Lefamulin最初由Nabriva开发,2018年3月仑胜医药获得在大中华区,包括中国大陆、香港、澳门、台湾开...查看全文
$Nabriva Therapeutics(NBRV)$ 8-K Current report, items 1.01, 1.02, 2.01, 5.02, 8.01, and 9.01 Accession Number: 0001104659-23-085605 Act: 34 Size: 853 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 8-K Current report, item 3.01 Accession Number: 0001104659-23-083250 Act: 34 Size: 199 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 3 Initial statement of beneficial ownership of securities Accession Number: 0001104659-23-079722 Size: 2 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 3 Initial statement of beneficial ownership of securities Accession Number: 0001104659-23-079724 Size: 3 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 8-K Current report, items 5.02 and 9.01 Accession Number: 0001104659-23-079156 Act: 34 Size: 507 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 8-K Current report, item 3.01 Accession Number: 0001104659-23-067071 Act: 34 Size: 173 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001558370-23-010302 Act: 34 Size: 5 MB 网页链接
$Nabriva Therapeutics(NBRV)$ NT 10-Q Notification of inability to timely file Form 10-Q or 10-QSB Accession Number: 0001104659-23-060936 Act: 34 Size: 23 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 10-K Annual report [Section 13 and 15(d), not S-K Item 405] Accession Number: 0001558370-23-006062 Act: 34 Size: 11 MB 网页链接
$Nabriva Therapeutics(NBRV)$ NT 10-K Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 Accession Number: 0001104659-23-040216 Act: 34 Size: 24 KB 网页链接